Edwards Lifesciences · Multi-Quarter Financial Trends

16 quarters · As reported by the company · Amounts in USD billions← EW

Quarter	Period End	Revenue ($B)	YoY	Gross Margin	Operating Income ($B)	Net Income ($B)	Net Margin	Free Cash Flow ($B)	EPS	Buybacks ($B)	Dividends ($B)
FY2026 Q2	2026-06-30	1.74	+13.6%	77.5%	0.51	0.24	13.9%	0.59	0.42	0.15	—
FY2026 Q1	2026-03-31	1.65	+16.7%	78.0%	0.48	0.38	23.1%	-0.02	0.66	0.42	—
FY2025 Q4	2025-12-31	1.57	+13.3%	78.1%	0.15	0.09	5.8%	0.35	0.16	0.04	—
FY2025 Q3	2025-09-30	1.55	+14.7%	77.8%	0.31	0.29	18.7%	0.52	0.50	0.59	—
FY2025 Q2	2025-06-30	1.53	+11.9%	77.5%	0.41	0.33	21.7%	0.24	0.56	0.01	—
FY2025 Q1	2025-03-31	1.41	+6.2%	78.7%	0.39	0.36	25.3%	0.22	0.61	0.26	—
FY2024 Q4	2024-12-31	1.39	+9.4%	—	—	0.39	27.8%	-0.18	0.65	0.10	—
FY2024 Q3	2024-09-30	1.35	+8.9%	80.6%	0.35	3.07	226.7%	0.30	5.13	0.90	—
FY2024 Q2	2024-06-30	1.37	+7.1%	79.9%	0.37	0.37	26.7%	0.29	0.61	0.16	—
FY2024 Q1	2024-03-31	1.33	+8.9%	78.4%	0.35	0.35	26.5%	-0.12	0.58	0.00	—
FY2023 Q4	2023-12-31	1.27	+194.6%	—	—	0.37	29.2%	0.05	0.61	0.45	—
FY2023 Q3	2023-09-30	1.24	−5.7%	79.8%	0.37	0.38	31.0%	0.36	0.63	0.17	—
FY2023 Q2	2023-06-30	1.28	—	79.9%	0.26	0.31	24.0%	-0.01	0.50	0.01	—
FY2023 Q1	2023-03-31	1.22	—	73.0%	0.39	0.34	27.9%	0.25	0.56	0.25	—
FY2022 Q4	2022-12-31	0.43	—	123.0%	0.20	0.77	179.6%	0.21	0.65	0.87	—
FY2022 Q3	2022-09-30	1.32	—	80.8%	0.40	0.34	26.0%	0.25	0.55	0.10	—

Quarterly figures come from the company's 10-Q and 10-K filings. The fourth quarter is derived as the full year minus the first three quarters; cash flow items are converted from fiscal year-to-date totals into single quarters.